Your session is about to expire
← Back to Search
Crisaborole + PF-07038124 + NBUVB for Vitiligo
Study Summary
This trial is testing whether a certain type of drug can help improve vitiligo, a condition where patches of skin lose their color. The trial is double-blind, meaning neither the participants nor the researchers will know who is receiving the experimental treatment until the trial is over.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this study open to those aged 45 and older?
"In order for individuals to be considered for enrollment in this trial, they must lie between the ages of 18 and 75."
Are there any vacancies available to join this clinical research study?
"Indeed. The clinical trial is actively seeking participants and the information on clinicaltrials.gov corroborates this fact. It was first published on September 7th 2022 and was last updated on September 12th 2022, with a goal of recruiting 64 patients to one medical centre."
Has NBUVB phototherapy received authorization from the FDA?
"The safety of NBUVB phototherapy was estimated to be a 2 due its second phase status, indicating the presence of some data explicitly supporting its security but none concerning efficacy."
How many individuals are enrolled in the experimental research?
"Affirmative, the clinicaltrials.gov website states that this investigation is actively seeking participants. It was first posted on September 7th 2022 with a recent update on September 12th and requires 64 volunteers from a single site to complete the study."
Is my participation eligible for this experiment?
"This clinical trial is seeking 64 applicants who have been clinically diagnosed with vitiligo for a minimum of 3 months and must fall between the ages 18 to 75. Necessary criteria include: exhibiting BSA >= 0.5% on facial area, having F-VASI & Total VASI scores that are both =>0.5%, agreeing to treatment involving an affected BSA range of 3%-25%, remaining on any concurrent medication regimen without change for duration of study, avoiding exposure to ultraviolet light sources other than those requested by the research team during the study period, and providing signed informed consent in accordance with protocol stipulations."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger